• Access Pharmaceuticals Inc., of Dallas, said Rhei Pharmaceuticals HK Ltd., of Hong Kong, its MuGard partner in China, received marketing approval from Chinese regulators for the mucoadhesive oral wound product to treat oral mucositis in cancer patients.